Evidence map›Paper›PMID 42812258›Full record

ArticleFrontiers in oncology2026

Case Report: rapid clinical complete response to Iparomlimab and Tuvonralimab combined with radiotherapy and chemotherapy in a patient with MSS/pMMR locally advanced rectal cancer.

Jue Wang, Tao Yang, Jingrui Zhou, Weimin Chen, Guiwei Wang, Chaoyu Mei, Ziwei Chen, Jibiao Li, Tao Shen

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jue Wang *Department of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Tao Yang *Kunming Medical University, Kunming, Yunnan, China.
Jingrui ZhouDepartment of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Weimin ChenDepartment of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Guiwei WangDepartment of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Chaoyu MeiDepartment of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Ziwei ChenZhumadian Central Hospital, Zhumadian, Henan, China.
Jibiao LiDepartment of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Tao ShenDepartment of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the efficacy and safety of Iparomlimab and Tuvonralimab, a PD-1/CTLA-4 bispecific antibody, in combination with chemoradiotherapy for a patient with microsatellite stable/mismatch repair proficient (MSS/pMMR) locally advanced rectal cancer (LARC), and to analyze the mechanism of achieving short-term clinical complete response (cCR). Methods: This case report presents a 61-year-old male with stage cT3N2aM0 IIIB MSS/pMMR rectal cancer. The patient received neoadjuvant therapy with Iparomlimab and Tuvonralimab (300mg per dose) plus XELOX regimen chemotherapy and radiotherapy (45Gy/25F). Responses were regularly assessed via digital rectal examination, imaging, endoscopy, and pathology. Results: After treatment, clinical complete response (cCR) was initially evidenced by MRI at week 12 and subsequently confirmed by endoscopic assessment combined with pathologic biopsy at week 20. No grade 3 or higher immune-related adverse events occurred. At the last follow-up in March 2026, no recurrence was observed. Conclusion: This case suggests that Iparomlimab and Tuvonralimab combined with chemoradiotherapy may induce rapid cCR in MSS/pMMR LARC, offering a promising organ-preserving strategy through immunotherapy. Further large-sample studies are warranted.

Indexed as

combined immunotherapyimmune checkpoint inhibitorsIparomlimab and TuvonralimabMSS/pMMR rectal cancerPD-1/CTLA-4 bispecific antibody

Identifiers

PMID42812258
PMCPMC13619410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.